Cytek Biosciences, Inc. (CTKB)
| Market Cap | 528.19M +56.8% |
| Revenue (ttm) | 204.17M +3.6% |
| Net Income | -74.00M |
| EPS | -0.58 |
| Shares Out | 129.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 912,389 |
| Open | 4.240 |
| Previous Close | 4.330 |
| Day's Range | 4.021 - 4.450 |
| 52-Week Range | 2.900 - 6.180 |
| Beta | 1.19 |
| Analysts | Buy |
| Price Target | 5.69 (+39.12%) |
| Earnings Date | May 7, 2026 |
About CTKB
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek mu... [Read more]
Financial Performance
In 2025, Cytek Biosciences's revenue was $201.49 million, an increase of 0.52% compared to the previous year's $200.45 million. Losses were -$66.54 million, 1005.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CTKB stock is "Buy." The 12-month stock price target is $5.69, which is an increase of 39.12% from the latest price.
News
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
At CYTO 2026, Cytek will showcase its cell analysis solutions, including the public debut of a new 7-laser Cytek Borealis full spectrum flow cytometer.
Cytek Biosciences price target lowered to $4.75 from $5.50 at Stephens
Stephens lowered the firm’s price target on Cytek Biosciences (CTKB) to $4.75 from $5.50 and keeps an Overweight rating on the shares. While revenue was roughly in line and FY26…
Cytek Biosciences price target lowered to $5.50 from $6 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Cytek Biosciences (CTKB) to $5.50 from $6 and keeps an Equal Weight rating on the shares.
Cytek Biosciences Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 6% year-over-year to $44.1 million, led by strong U.S. instrument sales and double-digit growth in services and reagents. Recurring revenue rose to 35% of total, while net loss widened due to higher operating expenses. Full-year guidance of $205–$212 million was reaffirmed.
Cytek Biosciences Quarterly report: Q1 2026
Cytek Biosciences has published its Q1 2026 quarterly earnings report on May 7, 2026.
Cytek Biosciences Earnings release: Q1 2026
Cytek Biosciences released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Cytek Biosciences Slides: Q1 2026
Cytek Biosciences has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Cytek Biosciences Reports First Quarter 2026 Financial Results
FREMONT, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results f...
Cytek Biosciences Proxy statement: Proxy filing
Cytek Biosciences filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Cytek Biosciences Proxy statement: Proxy filing
Cytek Biosciences filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
FREMONT, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the first quarter...
Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
Cytek Biosciences celebrates one year of operations at its Singapore facility, which has enhanced Cytek's manufacturing capacity and regional service.
Cytek Biosciences Transcript: TD Cowen 46th Annual Health Care Conference
Revenue grew 1% to $201.5M in 2025, outpacing a declining market and expanding global reach. Product innovation, especially Aurora Evo, and recurring revenue from services and reagents drive growth. APAC and clinical markets are key priorities for 2026.
Cytek Biosciences Slides: TD Cowen 46th Annual Health Care Conference
Cytek Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on March 4, 2026.
Cytek Biosciences Earnings Call Transcript: Q4 2025
Record Q4 revenue and a return to growth in H2 2025 were driven by strong performance in APAC, EMEA, and recurring revenue streams. Despite higher operating expenses and non-cash tax write-offs, liquidity remains strong, and 2026 guidance anticipates continued growth and positive adjusted EBITDA.
Cytek Biosciences Annual report: Q4 2025
Cytek Biosciences has published its Q4 2025 annual report on February 26, 2026.
Cytek Biosciences Earnings release: Q4 2025
Cytek Biosciences released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
Cytek Biosciences Annual report: Q4 2025
Cytek Biosciences has published its Q4 2025 annual report on February 26, 2026.
Cytek Biosciences Slides: Q4 2025
Cytek Biosciences has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results...
Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference
FREMONT, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming ...
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and ...
Cytek Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
A leading cell analysis company reported $201 million in 2024 revenue, driven by market share gains, product innovation, and global expansion. Growth is expected to accelerate through 2026, supported by new product launches, increased reagent sales, and a balanced capital allocation strategy.
Cytek Biosciences Slides: 44th Annual J.P. Morgan Healthcare Conference
Cytek Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
Cytek Biosciences reports preliminary Q4 revenue $62M, consensus $56.99M
Reports preliminary FY25 revenue $201M, consensus $196.71M. “Our fourth quarter revenue growth over the prior year represents a meaningful acceleration of growth compared to the prior quarters in 2025...